Imaging studies for men with recurrent prostate cancer

We had previously reported on a presentation by Calais et al. earlier this year. … READ MORE …

Are “manograms” a viable option in prostate cancer screening and risk assessment?

For several years, Dr. Jelle Barentz in the Netherlands has been a prominent advocate for the idea that we might be able to use imaging methodologies (prostate “manograms”, like breast mammograms for women) to screen for risk of prostate cancer — either along with or instead of PSA testing. … READ MORE …

Gadolinium contrast and mpMRI scans

In his latest epistle to the medical community on the MedPage Today web site, prostate cancer patient Howard Wolinsky writes about the need (or lack of need) for the use of gadolinium-containing contrast agents associated with the conduct of multiparametric MRI (mpMRI) scans. … READ MORE …

Gallium-68 PSMA vs. fluorine-18 fluciclovine PET/CT scans

According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy. … READ MORE …

What did we learn at the AUA this year?

The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …

MRI and MRI-guided biopsies — a new Cochrane review

Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. … READ MORE …

Early data suggest 18F-DCFPyL PET/CT scans can change patient management

A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …